Clinical Trial Detail

NCT ID NCT03659136
Title The XENERA-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Boehringer Ingelheim
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Exemestane + Xentuzumab

Everolimus + Exemestane

Age Groups: adult senior

Additional content available in CKB BOOST